Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review

Tronina, Olga; Ślubowska, K.; Mikołajczyk-Korniak, N.; Komuda-Leszek, Ewa; Wieczorek-Godlewska, Renata; Łągiewska, B; Pacholczyk, Marek; Lisik, Wojciech; Kosieradzki, Maciej; Durlik, M.

doi:10.1016/j.transproceed.2017.01.077

Cited by 5 publications

(2 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The pathogenesis of fibrosing cholestatic hepatitis is unknown; however, literature reports the occurrence to be around 2%–15% of transplant recipients. 5 Studies have shown that despite viral eradication, a significant number of patients continued to develop progressive fibrosis. 6 , 7 At present, there are no standardized guidelines regarding starting of preemptive DAA in HCV+ donor transplants, although data overall point toward successful eradication of HCV infection with the use of DAA in such cases.…”

Section: Discussionmentioning

confidence: 99%

Fibrosing Cholestatic Hepatitis Masquerading Acute Rejection in Hepatitis C Virus–Positive Donor Liver Graft

et al. 2023

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Fibrosing Cholestatic Hepatitis Masquerading Acute Rejection in Hepatitis C Virus–Positive Donor Liver Graft

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Fibrosing Cholestatic Hepatitis (FCH), a dreaded complication of HCV recurrence, has been described in liver[ 184 , 185 ], renal[ 186 ] and heart[ 187 ] transplant recipients. It is seen in around 2%–15% of liver transplant recipients and causes significant morbidity and mortality[ 188 , 189 ].…”

Section: Fibrosing Cholestatic Hepatitis (Fch)mentioning

confidence: 99%

Revolution in the diagnosis and management of hepatitis C virus infection in current era

Hanif¹,

Majid²,

Luck³

et al. 2022

WJH

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection is a major global public health problem, particularly in developing part of the world. Significant advances have been made in the early diagnosis and treatment of the disease. Its management has been particularly revolutionized during the past two decades. In this review, we summarize the major advances in the diagnostic and management armamentarium for chronic HCV infection. The focus of the present review is on the newer directly acting anti-viral agents, which have revolutionized the management of chronic HCV infection. Management of uncomplicated chronic HCV infection and of specific complications and special at-risk populations of patients will be covered in detail. Despite the advent and approval of highly effective and well tolerable oral agents, still many challenges remain, particularly the affordability, the equitable distribution and access to later drugs. The World Health Organization aims to eliminate viral hepatitis including HCV by 2030 since its poses a major public health threat. There is an urgent need to ensure uniform and early access to diagnostic and therapeutic facilities throughout the world if the later goal has to be realized.

show abstract

Multiple drugs

2017

Reactions Weekly

View full text Add to dashboard Cite

Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review

Cited by 5 publications

References 58 publications

Fibrosing Cholestatic Hepatitis Masquerading Acute Rejection in Hepatitis C Virus–Positive Donor Liver Graft

Fibrosing Cholestatic Hepatitis Masquerading Acute Rejection in Hepatitis C Virus–Positive Donor Liver Graft

Revolution in the diagnosis and management of hepatitis C virus infection in current era

Multiple drugs

Contact Info

Product

Resources

About